IDH2 and acute myeloid leukemia: Mutations in IDH1 or IDH2, prevalent in gliomas [131, 132], AML [133–136], chondrosarcomas [137], and cholangiocarcinomas [138], confer neomorphic activity [129], converting α-KG to the oncometabolite D-2-hydroxyglutarate (D-2HG) [74].